Close

Depomed (DEPO): Favorable Court Ruling, Mostly Expected - Mizuho

Go back to Depomed (DEPO): Favorable Court Ruling, Mostly Expected - Mizuho

Mizuho Securities Downgrades DepoMed Inc (DEPO) to Neutral

October 4, 2016 6:24 AM EDT

Mizuho Securities downgraded DepoMed Inc (NASDAQ: DEPO) from Outperform to Neutral with a price target of $27.00 following recent outperformance.

Analyst Irina Koffler commented, "We downgrade to Neutral and reiterate our blended $27 PT as we think that valuation has gotten too rich for new... More

Janney Montgomery Scott Reiterates Buy as Court Rules in Favor of Depomed (DEPO)

October 3, 2016 7:55 AM EDT

Janney Montgomery Scott reiterated a Buy rating on DepoMed Inc (NASDAQ: DEPO), and raised the price target to $31.00 (from $28.00), following a court ruling in favor of the company. The Court issued an Order in favor of DEPO in its patent litigation against and secures Nucynta through... More